Abecassis Michael M 4

What Happened
Michael M. Abecassis, a director of PharmaCyte Biotech, was granted 119,170 derivative shares (reported as an award) on 2026-03-31. The filing shows an acquisition at $0.00 per share (no cash paid at grant). The award is a derivative security (options) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-02 (filed within the typical 2-business-day window).
• Quantity: 119,170 derivative shares (award) at $0.00 per share.
• Shares owned after transaction: not specified in the filing.
• Footnote: The options shall vest in full on the date of the issuer’s next annual meeting of stockholders, subject to Abecassis’s continued service.
• Remarks: Exhibit 24.1 — Power of Attorney included with the filing.

Context
This was a grant of derivative securities (options) that do not represent an immediate sale or purchase of common stock. Vesting is contingent on continued service and the company’s next annual meeting; such awards are common compensation for directors and do not by themselves indicate buying or selling sentiment.